

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

Section 1: Identification

Product name : Abamectin Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

Section 2: Hazard identification

GHS Classification

Acute toxicity (Inhalation) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure : Category 2 (Central nervous system)

Hazardous to the aquatic environment - acute hazard : Category 1

Hazardous to the aquatic environment - chronic hazard : Category 1

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H332 Harmful if inhaled.
H361fd Suspected of damaging fertility. Suspected of damag-

Abamectin Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 6029686-00009 Date of last issue: 04.04.2023
Date of first issue: 10.06.2020

ing the unborn child.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	>= 1 -< 2.5
2,6-Di-tert-butyl-p-cresol	128-37-0	>= 0.25 -< 1

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

		<p>If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.</p>
In case of skin contact	:	<p>In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.</p>
In case of eye contact	:	<p>Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.</p>
If swallowed	:	<p>If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.</p>
Most important symptoms and effects, both acute and delayed	:	<p>Harmful if inhaled. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.</p>
Protection of first-aiders	:	<p>First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).</p>
Notes to physician	:	<p>Treat symptomatically and supportively.</p>

Section 5: Fire-fighting measures

Suitable extinguishing media	:	<p>Water spray Alcohol-resistant foam Carbon dioxide (CO₂) Dry chemical</p>
Unsuitable extinguishing media	:	<p>None known.</p>
Specific hazards during fire-fighting	:	<p>Exposure to combustion products may be a hazard to health.</p>
Hazardous combustion products	:	<p>Carbon oxides</p>
Specific extinguishing methods	:	<p>Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.</p>
Special protective equipment for firefighters	:	<p>In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.</p>
Hazchem Code	:	<p>3Z</p>

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures	:	<p>Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).</p>
---	---	---

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Keep tightly closed.
Keep in a cool, well-ventilated place.

Abamectin Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 6029686-00009 Date of last issue: 04.04.2023
 Date of first issue: 10.06.2020

Materials to avoid : Store in accordance with the particular national regulations.
 : Do not store with the following product types:
 Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m ³ (OEB 3)	Internal
		Wipe limit	150 µg/100 cm ²	Internal
2,6-Di-tert-butyl-p-cresol	128-37-0	WES-TWA	10 mg/m ³	NZ OEL
	Further information: Skin sensitiser			
		TWA (Inhalable fraction and vapor)	2 mg/m ³	ACGIH

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type
 Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.
 Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
 Additional body garments should be used based upon the

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance	:	liquid
Colour	:	light yellow
Odour	:	characteristic
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	265 °C
Flash point	:	213.2 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	0.90 - 0.91
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	Not applicable

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

Acute toxicity

Harmful if inhaled.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: 2.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity	:	LD50 (Rat): 24 mg/kg
---------------------	---	----------------------

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupilAcute inhalation toxicity : LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mistAcute dermal toxicity : LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg**2,6-Di-tert-butyl-p-cresol:**Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg
Method: OECD Test Guideline 401Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity**Skin corrosion/irritation**

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**Species : Rabbit
Result : No skin irritation**2,6-Di-tert-butyl-p-cresol:**Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials**Serious eye damage/eye irritation**

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**Species : Rabbit
Result : Mild eye irritation**2,6-Di-tert-butyl-p-cresol:**Species : Rabbit
Result : No eye irritation

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

Method : OECD Test Guideline 405
Remarks : Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Test Type : Maximisation Test
Exposure routes : Skin contact
Result : Not a skin sensitizer.

2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)
Exposure routes : Skin contact
Species : Humans
Result : negative

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Abamectin Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 6029686-00009 Date of last issue: 04.04.2023
Date of first issue: 10.06.2020

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

- Result: Fetotoxicity
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed
- Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
Remarks: Adverse developmental effects were observed
- Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects
- Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.
- 2,6-Di-tert-butyl-p-cresol:**
- Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

- | | |
|-----------------|---|
| Exposure routes | : Ingestion |
| Target Organs | : Central nervous system |
| Assessment | : Causes damage to organs through prolonged or repeated |

Abamectin Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 6029686-00009 Date of last issue: 04.04.2023
Date of first issue: 10.06.2020

exposure.

2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.

Repeated dose toxicity**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system

2,6-Di-tert-butyl-p-cresol:

Species : Rat
NOAEL : 25 mg/kg
Application Route : Ingestion
Exposure time : 22 Months

Aspiration toxicity

Not classified based on available information.

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

Experience with human exposure**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

Section 12: Ecological information**Ecotoxicity****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

<p>Toxicity to fish</p> <p>LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l Exposure time: 96 h</p> <p>LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l Exposure time: 96 h</p> <p>LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l Exposure time: 96 h</p> <p>LC50 (Cyprinus carpio (Carp)): 42 µg/l Exposure time: 96 h</p> <p>LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l Exposure time: 96 h</p>	<p>Toxicity to daphnia and other aquatic invertebrates</p> <p>EC50 (Americamysis): 0.022 µg/l Exposure time: 96 h</p> <p>EC50 (Daphnia magna (Water flea)): 0.34 µg/l Exposure time: 48 h</p>
<p>Toxicity to algae/aquatic plants</p> <p>EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h</p>	<p>M-Factor (Acute aquatic toxicity)</p> <p>10,000</p>
<p>Toxicity to fish (Chronic toxicity)</p> <p>NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l Exposure time: 32 d</p>	<p>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</p> <p>NOEC (Daphnia magna (Water flea)): 0.03 µg/l Exposure time: 21 d</p> <p>NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l Exposure time: 28 d</p>
<p>M-Factor (Chronic aquatic</p>	<p>10,000</p>

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

toxicity)

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0.57 mg/l
Exposure time: 96 h
Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.48 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1

Toxicity to fish (Chronic toxicity) : NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l
Exposure time: 30 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.316 mg/l
Exposure time: 21 d

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 10,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Stability in water : Hydrolysis: 50 %(< 12 h)

2,6-Di-tert-butyl-p-cresol:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 4.5 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

Bioaccumulative potential**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

2,6-Di-tert-butyl-p-cresol:Bioaccumulation : Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n-octanol/water : log Pow: 5.1

Mobility in soil**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log Koc: > 3.6

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

IATA-DGR

UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passenger aircraft)	:	964
Environmentally hazardous	:	yes

IMDG-Code

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)
Class	:	9
Packing group	:	III
Labels	:	9
Hazchem Code	:	3Z
Marine pollutant	:	no

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

HSNO Approval Number

HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

Section 16: Other information

Revision Date : 30.09.2023

Further informationSources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships;

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	6029686-00009	Date of first issue: 10.06.2020

n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN